Tag: locally advanced pancreatic cancer market key players

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Locally Advanced Pancreatic Cancer Market Growth Analysis: How Will Revenue Expand During The Forecast Period?

The market for locally advanced pancreatic cancer experienced a significant upswing recently, projecting an expansion from $1.05 billion in 2025 to $1.16 billion by 2026, driven by a compound annual growth rate of 10.5%. This historical expansion was fueled by factors such as late detection of pancreatic cancer, a restricted number of patients eligible for surgery when the disease is locally advanced, the long-standing prevalence of gemcitabine chemotherapy, unsatisfactory overall survival statistics, and an increase in hospital-based cancer treatment services.

The market for locally advanced pancreatic cancer is poised for significant expansion in the coming years, projected to reach an impressive $1.71 billion by 2030, fueled by a compound annual growth rate of 10.2%. This anticipated surge is underpinned by several key drivers, including the broader implementation of combination therapy strategies, a rise in the utilization of Stereotactic Body Radiation Therapy (SBRT), increased financial backing for pancreatic cancer investigations, a heightened emphasis on tailored cancer treatments, and the expanding accessibility of state-of-the-art medical facilities. During this forecast period, prominent market developments are expected to involve a greater incorporation of combined chemotherapy treatments, a growing trend towards the use of neoadjuvant therapies, a more concentrated effort on reducing tumor size to improve surgical candidacy, an amplified role for radiation therapy in managing localized disease, and a stronger commitment to integrated treatment strategy development involving various medical specialties.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21214&type=smp

Locally Advanced Pancreatic Cancer Market Demand Drivers Creating New Revenue Opportunities

Heightened tobacco usage is anticipated to be a primary catalyst for the expansion of markets focused on locally advanced pancreatic cancer. Tobacco, derived from a plant whose leaves are processed into items like cigarettes and cigars, contains nicotine, a substance recognized for its addictive properties and strong association with severe health conditions, including cancer and cardiac ailments. Several elements contribute to the escalating prevalence of tobacco consumption, such as readily available access, economic feasibility, aggressive marketing strategies employed by tobacco companies, the societal acceptance observed in certain regions, and smoking as a coping mechanism for stress. Given that tobacco consumption significantly elevates the risk of developing locally advanced pancreatic cancer by contributing to a higher occurrence of pancreatic tumors, its role in market growth is pronounced. As an illustration, a study released in October 2024 by the European Respiratory Society (ERS), a non-profit entity based in Switzerland, highlighted a substantial upswing in smoking tendencies among younger demographics, demonstrating an increase from 22.5% of participants who were smokers in 2022 to 40.1% in 2024. Consequently, the escalating consumption of tobacco is directly fueling the progression of the locally advanced pancreatic cancer market.

Locally Advanced Pancreatic Cancer Market Segment Analysis And Revenue Opportunities

The locally advanced pancreatic cancer market covered in this report is segmented –

1) By Therapy: Chemotherapy, Radiation Therapy

2) By Route Of Administration: Oral, Injectables, Other Routes Of Administrations

3) By End-User: Hospital, Specialty Clinics, Research Institutions, Other End-Users

Subsegments:

1) By Chemotherapy: Gemcitabine-based Chemotherapy, FOLFIRINOX Chemotherapy

2) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Body Radiation Therapy (SBRT)

Locally Advanced Pancreatic Cancer Market Trends Driving Strategic Industry Expansion

In the market for locally advanced pancreatic cancer, key players are concentrating on creating novel therapeutic agents, including orphan drugs. These efforts aim to expand treatment availability, improve patient results, and tackle the significant unmet medical requirements presented by this challenging illness. Orphan drugs, intended for rare conditions affecting limited populations, receive encouragement through governmental incentives like tax breaks and periods of market exclusivity to foster their creation. As an illustration, in January 2025, Actuate Therapeutics Inc., a pharmaceutical entity based in the United States, revealed that their investigational compound, Elraglusib, identified as a GSK-3ß inhibitor, had been granted Orphan Drug Designation by both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the management of pancreatic ductal adenocarcinoma (PDAC), a form of locally advanced pancreatic cancer. This designation underscores its promise in addressing a crucial therapeutic void for this severe cancer, particularly following encouraging outcomes from Phase 2 clinical trials that demonstrated notable clinical benefits and anti-cancer activity in patients with metastatic PDAC.

Locally Advanced Pancreatic Cancer Market Leading Players Shaping Industry Direction

Major companies operating in the locally advanced pancreatic cancer market are Pfizer Inc, F Hoffmann La Roche Ltd, Merck and Co Inc, Bristol Myers Squibb Company, AstraZeneca plc, AbbVie Inc, Novartis AG, GSK plc, Bayer AG, Eli Lilly and Company, Ipsen, Takeda Pharmaceutical Company Limited, Amgen Inc, Sanofi, Servier, NovoCure Limited, Halozyme Therapeutics, Clovis Oncology, Astellas Pharma, BeiGene

Access The Complete Locally Advanced Pancreatic Cancer Market Report:

https://www.thebusinessresearchcompany.com/report/locally-advanced-pancreatic-cancer-global-market-report

Locally Advanced Pancreatic Cancer Market Geographic Analysis: Where Is Demand Growing The Fastest?

North Americawas the largest region in the locally advanced pancreatic cancer market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Locally Advanced Pancreatic Cancer Market Growth Analysis: How Will Revenue Expand During The Forecast Period?

The market for locally advanced pancreatic cancer experienced a significant upswing recently, projecting an expansion from $1.05 billion in 2025 to $1.16 billion by 2026, driven by a compound annual growth rate of 10.5%. This historical expansion was fueled by factors such as late detection of pancreatic cancer, a restricted number of patients eligible for surgery when the disease is locally advanced, the long-standing prevalence of gemcitabine chemotherapy, unsatisfactory overall survival statistics, and an increase in hospital-based cancer treatment services.

The market for locally advanced pancreatic cancer is poised for significant expansion in the coming years, projected to reach an impressive $1.71 billion by 2030, fueled by a compound annual growth rate of 10.2%. This anticipated surge is underpinned by several key drivers, including the broader implementation of combination therapy strategies, a rise in the utilization of Stereotactic Body Radiation Therapy (SBRT), increased financial backing for pancreatic cancer investigations, a heightened emphasis on tailored cancer treatments, and the expanding accessibility of state-of-the-art medical facilities. During this forecast period, prominent market developments are expected to involve a greater incorporation of combined chemotherapy treatments, a growing trend towards the use of neoadjuvant therapies, a more concentrated effort on reducing tumor size to improve surgical candidacy, an amplified role for radiation therapy in managing localized disease, and a stronger commitment to integrated treatment strategy development involving various medical specialties.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21214&type=smp

Locally Advanced Pancreatic Cancer Market Demand Drivers Creating New Revenue Opportunities

Heightened tobacco usage is anticipated to be a primary catalyst for the expansion of markets focused on locally advanced pancreatic cancer. Tobacco, derived from a plant whose leaves are processed into items like cigarettes and cigars, contains nicotine, a substance recognized for its addictive properties and strong association with severe health conditions, including cancer and cardiac ailments. Several elements contribute to the escalating prevalence of tobacco consumption, such as readily available access, economic feasibility, aggressive marketing strategies employed by tobacco companies, the societal acceptance observed in certain regions, and smoking as a coping mechanism for stress. Given that tobacco consumption significantly elevates the risk of developing locally advanced pancreatic cancer by contributing to a higher occurrence of pancreatic tumors, its role in market growth is pronounced. As an illustration, a study released in October 2024 by the European Respiratory Society (ERS), a non-profit entity based in Switzerland, highlighted a substantial upswing in smoking tendencies among younger demographics, demonstrating an increase from 22.5% of participants who were smokers in 2022 to 40.1% in 2024. Consequently, the escalating consumption of tobacco is directly fueling the progression of the locally advanced pancreatic cancer market.

Locally Advanced Pancreatic Cancer Market Segment Analysis And Revenue Opportunities

The locally advanced pancreatic cancer market covered in this report is segmented –

1) By Therapy: Chemotherapy, Radiation Therapy

2) By Route Of Administration: Oral, Injectables, Other Routes Of Administrations

3) By End-User: Hospital, Specialty Clinics, Research Institutions, Other End-Users

Subsegments:

1) By Chemotherapy: Gemcitabine-based Chemotherapy, FOLFIRINOX Chemotherapy

2) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Body Radiation Therapy (SBRT)

Locally Advanced Pancreatic Cancer Market Trends Driving Strategic Industry Expansion

In the market for locally advanced pancreatic cancer, key players are concentrating on creating novel therapeutic agents, including orphan drugs. These efforts aim to expand treatment availability, improve patient results, and tackle the significant unmet medical requirements presented by this challenging illness. Orphan drugs, intended for rare conditions affecting limited populations, receive encouragement through governmental incentives like tax breaks and periods of market exclusivity to foster their creation. As an illustration, in January 2025, Actuate Therapeutics Inc., a pharmaceutical entity based in the United States, revealed that their investigational compound, Elraglusib, identified as a GSK-3ß inhibitor, had been granted Orphan Drug Designation by both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the management of pancreatic ductal adenocarcinoma (PDAC), a form of locally advanced pancreatic cancer. This designation underscores its promise in addressing a crucial therapeutic void for this severe cancer, particularly following encouraging outcomes from Phase 2 clinical trials that demonstrated notable clinical benefits and anti-cancer activity in patients with metastatic PDAC.

Locally Advanced Pancreatic Cancer Market Leading Players Shaping Industry Direction

Major companies operating in the locally advanced pancreatic cancer market are Pfizer Inc, F Hoffmann La Roche Ltd, Merck and Co Inc, Bristol Myers Squibb Company, AstraZeneca plc, AbbVie Inc, Novartis AG, GSK plc, Bayer AG, Eli Lilly and Company, Ipsen, Takeda Pharmaceutical Company Limited, Amgen Inc, Sanofi, Servier, NovoCure Limited, Halozyme Therapeutics, Clovis Oncology, Astellas Pharma, BeiGene

Access The Complete Locally Advanced Pancreatic Cancer Market Report:

https://www.thebusinessresearchcompany.com/report/locally-advanced-pancreatic-cancer-global-market-report

Locally Advanced Pancreatic Cancer Market Geographic Analysis: Where Is Demand Growing The Fastest?

North Americawas the largest region in the locally advanced pancreatic cancer market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Locally Advanced Pancreatic Cancer Market Growth Analysis: How Will Revenue Expand During The Forecast Period?

The market for locally advanced pancreatic cancer experienced a significant upswing recently, projecting an expansion from $1.05 billion in 2025 to $1.16 billion by 2026, driven by a compound annual growth rate of 10.5%. This historical expansion was fueled by factors such as late detection of pancreatic cancer, a restricted number of patients eligible for surgery when the disease is locally advanced, the long-standing prevalence of gemcitabine chemotherapy, unsatisfactory overall survival statistics, and an increase in hospital-based cancer treatment services.

The market for locally advanced pancreatic cancer is poised for significant expansion in the coming years, projected to reach an impressive $1.71 billion by 2030, fueled by a compound annual growth rate of 10.2%. This anticipated surge is underpinned by several key drivers, including the broader implementation of combination therapy strategies, a rise in the utilization of Stereotactic Body Radiation Therapy (SBRT), increased financial backing for pancreatic cancer investigations, a heightened emphasis on tailored cancer treatments, and the expanding accessibility of state-of-the-art medical facilities. During this forecast period, prominent market developments are expected to involve a greater incorporation of combined chemotherapy treatments, a growing trend towards the use of neoadjuvant therapies, a more concentrated effort on reducing tumor size to improve surgical candidacy, an amplified role for radiation therapy in managing localized disease, and a stronger commitment to integrated treatment strategy development involving various medical specialties.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21214&type=smp

Locally Advanced Pancreatic Cancer Market Demand Drivers Creating New Revenue Opportunities

Heightened tobacco usage is anticipated to be a primary catalyst for the expansion of markets focused on locally advanced pancreatic cancer. Tobacco, derived from a plant whose leaves are processed into items like cigarettes and cigars, contains nicotine, a substance recognized for its addictive properties and strong association with severe health conditions, including cancer and cardiac ailments. Several elements contribute to the escalating prevalence of tobacco consumption, such as readily available access, economic feasibility, aggressive marketing strategies employed by tobacco companies, the societal acceptance observed in certain regions, and smoking as a coping mechanism for stress. Given that tobacco consumption significantly elevates the risk of developing locally advanced pancreatic cancer by contributing to a higher occurrence of pancreatic tumors, its role in market growth is pronounced. As an illustration, a study released in October 2024 by the European Respiratory Society (ERS), a non-profit entity based in Switzerland, highlighted a substantial upswing in smoking tendencies among younger demographics, demonstrating an increase from 22.5% of participants who were smokers in 2022 to 40.1% in 2024. Consequently, the escalating consumption of tobacco is directly fueling the progression of the locally advanced pancreatic cancer market.

Locally Advanced Pancreatic Cancer Market Segment Analysis And Revenue Opportunities

The locally advanced pancreatic cancer market covered in this report is segmented –

1) By Therapy: Chemotherapy, Radiation Therapy

2) By Route Of Administration: Oral, Injectables, Other Routes Of Administrations

3) By End-User: Hospital, Specialty Clinics, Research Institutions, Other End-Users

Subsegments:

1) By Chemotherapy: Gemcitabine-based Chemotherapy, FOLFIRINOX Chemotherapy

2) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Body Radiation Therapy (SBRT)

Locally Advanced Pancreatic Cancer Market Trends Driving Strategic Industry Expansion

In the market for locally advanced pancreatic cancer, key players are concentrating on creating novel therapeutic agents, including orphan drugs. These efforts aim to expand treatment availability, improve patient results, and tackle the significant unmet medical requirements presented by this challenging illness. Orphan drugs, intended for rare conditions affecting limited populations, receive encouragement through governmental incentives like tax breaks and periods of market exclusivity to foster their creation. As an illustration, in January 2025, Actuate Therapeutics Inc., a pharmaceutical entity based in the United States, revealed that their investigational compound, Elraglusib, identified as a GSK-3ß inhibitor, had been granted Orphan Drug Designation by both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the management of pancreatic ductal adenocarcinoma (PDAC), a form of locally advanced pancreatic cancer. This designation underscores its promise in addressing a crucial therapeutic void for this severe cancer, particularly following encouraging outcomes from Phase 2 clinical trials that demonstrated notable clinical benefits and anti-cancer activity in patients with metastatic PDAC.

Locally Advanced Pancreatic Cancer Market Leading Players Shaping Industry Direction

Major companies operating in the locally advanced pancreatic cancer market are Pfizer Inc, F Hoffmann La Roche Ltd, Merck and Co Inc, Bristol Myers Squibb Company, AstraZeneca plc, AbbVie Inc, Novartis AG, GSK plc, Bayer AG, Eli Lilly and Company, Ipsen, Takeda Pharmaceutical Company Limited, Amgen Inc, Sanofi, Servier, NovoCure Limited, Halozyme Therapeutics, Clovis Oncology, Astellas Pharma, BeiGene

Access The Complete Locally Advanced Pancreatic Cancer Market Report:

https://www.thebusinessresearchcompany.com/report/locally-advanced-pancreatic-cancer-global-market-report

Locally Advanced Pancreatic Cancer Market Geographic Analysis: Where Is Demand Growing The Fastest?

North Americawas the largest region in the locally advanced pancreatic cancer market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Value Trend Is Expected For The Locally Advanced Pancreatic Cancer Market From 2026 To 2030?

The market for locally advanced pancreatic cancer has seen significant expansion in recent years. Projections indicate it will expand from $1.05 billion in 2025 to reach $1.16 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 10.5%. Historically, this expansion can be linked to factors such as the late-stage identification of pancreatic cancer, restricted surgical options for locally advanced instances, the traditional dependence on gemcitabine-based chemotherapy, low overall patient survival rates, and the increase in hospital-based oncology services.

The market size for locally advanced pancreatic cancer is projected to experience substantial expansion in the coming years. This market is predicted to reach $1.71 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.2%. Several factors will drive this growth during the forecast period, including the broadening of combination therapy protocols, the increasing uptake of SBRT, heightened investment in pancreatic cancer research, a rising emphasis on personalized oncology care, and the growing accessibility of advanced treatment centers. Key trends anticipated within the forecast period encompass a greater utilization of combination chemotherapy regimens, the expanding adoption of neoadjuvant treatment strategies, a heightened focus on tumor downstaging to improve surgical eligibility, the broadened application of radiation therapy for localized disease control, and an increasing emphasis on multidisciplinary treatment planning.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21214&type=smp

What Key Growth Drivers Are Influencing The Locally Advanced Pancreatic Cancer Market?

The rising use of tobacco is expected to propel the growth of the locally advanced pancreatic cancer markets in the future. Tobacco, a plant whose leaves are utilized in items like cigarettes and cigars, contains nicotine, which is addictive and associated with serious health conditions such as cancer and heart disease. The increase in tobacco consumption is influenced by factors including easy accessibility, affordability, tobacco marketing efforts, social acceptance in certain areas, and stress-related smoking. Tobacco use is a significant risk factor for the development of locally advanced pancreatic cancer, as it contributes to a higher incidence of pancreatic malignancies. For example, in October 2024, a study from the European Respiratory Society’s (ERS), a Switzerland-based non-profit organization, examining smoking trends among young people revealed a notable surge in smoking rates, with 22.5% of respondents smoking in 2022 compared to 40.1% in 2024. Therefore, the increased tobacco consumption is driving the expansion of the locally advanced pancreatic cancer market.

What Are The Core Segment Classifications In The Locally Advanced Pancreatic Cancer Market?

The locally advanced pancreatic cancer market covered in this report is segmented –

1) By Therapy: Chemotherapy, Radiation Therapy

2) By Route Of Administration: Oral, Injectables, Other Routes Of Administrations

3) By End-User: Hospital, Specialty Clinics, Research Institutions, Other End-Users

Subsegments:

1) By Chemotherapy: Gemcitabine-based Chemotherapy, FOLFIRINOX Chemotherapy

2) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Body Radiation Therapy (SBRT)

Which Trends Are Affecting The Locally Advanced Pancreatic Cancer Market Framework?

Companies operating in the locally advanced pancreatic cancer market are primarily focused on developing novel products, such as orphan drugs, to enhance treatment options, improve patient outcomes, and address the unmet medical needs associated with this aggressive disease. Orphan drugs are specifically designed to treat rare diseases affecting a small demographic and are incentivized by regulatory authorities with benefits like tax reductions and market exclusivity to encourage their development. For instance, in January 2025, Actuate Therapeutics Inc., a US-based biopharmaceutical company, announced that its Elraglusib, a new GSK-3β inhibitor, received Orphan Drug Designation from both the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) for treating pancreatic ductal adenocarcinoma (PDAC) (a potential types of locally advanced pancreatic cancer). This recognition underscores its potential to fill a critical gap in treating this severe cancer, particularly following promising Phase 2 trial results demonstrating significant clinical improvements and anti-tumor effects in metastatic PDAC patients.

Which Companies Are Influencing The Locally Advanced Pancreatic Cancer Market?

Major companies operating in the locally advanced pancreatic cancer market are Pfizer Inc, F Hoffmann La Roche Ltd, Merck and Co Inc, Bristol Myers Squibb Company, AstraZeneca plc, AbbVie Inc, Novartis AG, GSK plc, Bayer AG, Eli Lilly and Company, Ipsen, Takeda Pharmaceutical Company Limited, Amgen Inc, Sanofi, Servier, NovoCure Limited, Halozyme Therapeutics, Clovis Oncology, Astellas Pharma, BeiGene

Access The Complete Locally Advanced Pancreatic Cancer Market Report:

https://www.thebusinessresearchcompany.com/report/locally-advanced-pancreatic-cancer-global-market-report

Which Region Holds The Largest Share In The Locally Advanced Pancreatic Cancer Market?

North America was the largest region in the locally advanced pancreatic cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Locally Advanced Pancreatic Cancer Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=21214&type=smp

Browse Through More Reports Similar to the Global Locally Advanced Pancreatic Cancer Market 2026, By The Business Research Company

Invasive Ductal Carcinoma Therapeutics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/invasive-ductal-carcinoma-therapeutics-global-market-report

Pancreatic Cancer Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

Gastroesophageal Junction Adenocarcinoma Therapeutics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroesophageal-junction-adenocarcinoma-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Locally Advanced Pancreatic Cancer Market Projected To Reach By 2030?

The market for locally advanced pancreatic cancer has witnessed substantial growth over recent years. This market is projected to expand from $1.05 billion in 2025 to $1.16 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.5%. Factors contributing to this historical growth include the prevalence of late-stage diagnosis of pancreatic cancer, restricted surgical eligibility for locally advanced cases, a past dependence on gemcitabine-based chemotherapy, low overall survival rates, and an increase in hospital-based oncology care.

The market for locally advanced pancreatic cancer is projected to experience swift expansion over the coming years. This market is anticipated to reach $1.71 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.2%. Several factors are fueling this growth during the projection period, including the broadening of combination therapy protocols, the greater acceptance of SBRT, heightened investment in pancreatic cancer research, an intensifying focus on tailored oncology care, and the increasing presence of specialized treatment facilities. Key developments expected during this forecast period encompass the augmented use of combination chemotherapy regimens, an expanding embrace of neoadjuvant treatment methods, a heightened emphasis on reducing tumor size for surgical suitability, the wider application of radiation therapy for managing local disease, and a stronger focus on collaborative treatment strategies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21214&type=smp

What Key Factors Are Affecting The Locally Advanced Pancreatic Cancer Market Demand?

Future expansion in the locally advanced pancreatic cancer markets is anticipated to be propelled by the rise in tobacco consumption. Tobacco is a plant with leaves processed into items like cigarettes and cigars. This plant contains addictive nicotine, associated with severe health problems including cancer and heart disease. The growing use of tobacco stems from various factors, namely its ready availability, reasonable cost, marketing strategies, cultural acceptance in certain regions, and smoking in response to stress. Consumption of tobacco poses a substantial risk for developing locally advanced pancreatic cancer, leading to a higher occurrence of pancreatic malignancies. For example, an October 2024 study on youth smoking trends by the European Respiratory Society’s (ERS), a Switzerland-based non-profit, showed a notable increase in smoking prevalence, with 22.5% of respondents smoking in 2022 rising to 40.1% in 2024. Consequently, the surge in tobacco consumption is fueling the expansion of the locally advanced pancreatic cancer market.

Which Segment Classifications Are Used In The Locally Advanced Pancreatic Cancer Market Segment Analysis?

The locally advanced pancreatic cancer market covered in this report is segmented –

1) By Therapy: Chemotherapy, Radiation Therapy

2) By Route Of Administration: Oral, Injectables, Other Routes Of Administrations

3) By End-User: Hospital, Specialty Clinics, Research Institutions, Other End-Users

Subsegments:

1) By Chemotherapy: Gemcitabine-based Chemotherapy, FOLFIRINOX Chemotherapy

2) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Body Radiation Therapy (SBRT)

What Trends Are Influencing Changes In The Locally Advanced Pancreatic Cancer Market?

Leading companies in the locally advanced pancreatic cancer market are concentrating on creating innovative products, such as orphan drugs, to improve treatment options, enhance patient outcomes, and address the unmet medical needs associated with this aggressive disease. Orphan drugs are specifically developed to treat rare conditions affecting a small number of individuals, and authorities provide incentives like tax reductions and market exclusivity to encourage their development. For instance, in January 2025, Actuate Therapeutics Inc., a US-based biopharmaceutical company, announced that its Elraglusib, a new GSK-3ß inhibitor, received Orphan Drug Designation from both the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) for the treatment of pancreatic ductal adenocarcinoma (PDAC), a potential type of locally advanced pancreatic cancer. This recognition emphasizes its potential to fulfill a vital need in treating this severe cancer, especially given the promising Phase 2 trial results that showed significant clinical improvements and anti-tumor effects in metastatic PDAC patients.

Which Firms Are Contributing To The Locally Advanced Pancreatic Cancer Market Ecosystem?

Major companies operating in the locally advanced pancreatic cancer market are Pfizer Inc, F Hoffmann La Roche Ltd, Merck and Co Inc, Bristol Myers Squibb Company, AstraZeneca plc, AbbVie Inc, Novartis AG, GSK plc, Bayer AG, Eli Lilly and Company, Ipsen, Takeda Pharmaceutical Company Limited, Amgen Inc, Sanofi, Servier, NovoCure Limited, Halozyme Therapeutics, Clovis Oncology, Astellas Pharma, BeiGene

Get The Full Locally Advanced Pancreatic Cancer Market Report:

https://www.thebusinessresearchcompany.com/report/locally-advanced-pancreatic-cancer-global-market-report

Where Is The Locally Advanced Pancreatic Cancer Market Primarily Concentrated By Region?

North America was the largest region in the locally advanced pancreatic cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Locally Advanced Pancreatic Cancer Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/locally-advanced-pancreatic-cancer-global-market-report

Browse Through More Reports Similar to the Global Locally Advanced Pancreatic Cancer Market 2026, By The Business Research Company

Invasive Ductal Carcinoma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/invasive-ductal-carcinoma-therapeutics-global-market-report

Pancreatic Cancer Drugs Market Report

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

Gastroesophageal Junction Adenocarcinoma Therapeutics Market Report

https://www.thebusinessresearchcompany.com/report/gastroesophageal-junction-adenocarcinoma-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Locally Advanced Pancreatic Cancer Market Projected To Reach By 2030?

The market for locally advanced pancreatic cancer has witnessed substantial growth over recent years. This market is projected to expand from $1.05 billion in 2025 to $1.16 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.5%. Factors contributing to this historical growth include the prevalence of late-stage diagnosis of pancreatic cancer, restricted surgical eligibility for locally advanced cases, a past dependence on gemcitabine-based chemotherapy, low overall survival rates, and an increase in hospital-based oncology care.

The market for locally advanced pancreatic cancer is projected to experience swift expansion over the coming years. This market is anticipated to reach $1.71 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.2%. Several factors are fueling this growth during the projection period, including the broadening of combination therapy protocols, the greater acceptance of SBRT, heightened investment in pancreatic cancer research, an intensifying focus on tailored oncology care, and the increasing presence of specialized treatment facilities. Key developments expected during this forecast period encompass the augmented use of combination chemotherapy regimens, an expanding embrace of neoadjuvant treatment methods, a heightened emphasis on reducing tumor size for surgical suitability, the wider application of radiation therapy for managing local disease, and a stronger focus on collaborative treatment strategies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21214&type=smp

What Key Factors Are Affecting The Locally Advanced Pancreatic Cancer Market Demand?

Future expansion in the locally advanced pancreatic cancer markets is anticipated to be propelled by the rise in tobacco consumption. Tobacco is a plant with leaves processed into items like cigarettes and cigars. This plant contains addictive nicotine, associated with severe health problems including cancer and heart disease. The growing use of tobacco stems from various factors, namely its ready availability, reasonable cost, marketing strategies, cultural acceptance in certain regions, and smoking in response to stress. Consumption of tobacco poses a substantial risk for developing locally advanced pancreatic cancer, leading to a higher occurrence of pancreatic malignancies. For example, an October 2024 study on youth smoking trends by the European Respiratory Society’s (ERS), a Switzerland-based non-profit, showed a notable increase in smoking prevalence, with 22.5% of respondents smoking in 2022 rising to 40.1% in 2024. Consequently, the surge in tobacco consumption is fueling the expansion of the locally advanced pancreatic cancer market.

Which Segment Classifications Are Used In The Locally Advanced Pancreatic Cancer Market Segment Analysis?

The locally advanced pancreatic cancer market covered in this report is segmented –

1) By Therapy: Chemotherapy, Radiation Therapy

2) By Route Of Administration: Oral, Injectables, Other Routes Of Administrations

3) By End-User: Hospital, Specialty Clinics, Research Institutions, Other End-Users

Subsegments:

1) By Chemotherapy: Gemcitabine-based Chemotherapy, FOLFIRINOX Chemotherapy

2) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Body Radiation Therapy (SBRT)

What Trends Are Influencing Changes In The Locally Advanced Pancreatic Cancer Market?

Leading companies in the locally advanced pancreatic cancer market are concentrating on creating innovative products, such as orphan drugs, to improve treatment options, enhance patient outcomes, and address the unmet medical needs associated with this aggressive disease. Orphan drugs are specifically developed to treat rare conditions affecting a small number of individuals, and authorities provide incentives like tax reductions and market exclusivity to encourage their development. For instance, in January 2025, Actuate Therapeutics Inc., a US-based biopharmaceutical company, announced that its Elraglusib, a new GSK-3ß inhibitor, received Orphan Drug Designation from both the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) for the treatment of pancreatic ductal adenocarcinoma (PDAC), a potential type of locally advanced pancreatic cancer. This recognition emphasizes its potential to fulfill a vital need in treating this severe cancer, especially given the promising Phase 2 trial results that showed significant clinical improvements and anti-tumor effects in metastatic PDAC patients.

Which Firms Are Contributing To The Locally Advanced Pancreatic Cancer Market Ecosystem?

Major companies operating in the locally advanced pancreatic cancer market are Pfizer Inc, F Hoffmann La Roche Ltd, Merck and Co Inc, Bristol Myers Squibb Company, AstraZeneca plc, AbbVie Inc, Novartis AG, GSK plc, Bayer AG, Eli Lilly and Company, Ipsen, Takeda Pharmaceutical Company Limited, Amgen Inc, Sanofi, Servier, NovoCure Limited, Halozyme Therapeutics, Clovis Oncology, Astellas Pharma, BeiGene

Get The Full Locally Advanced Pancreatic Cancer Market Report:

https://www.thebusinessresearchcompany.com/report/locally-advanced-pancreatic-cancer-global-market-report

Where Is The Locally Advanced Pancreatic Cancer Market Primarily Concentrated By Region?

North America was the largest region in the locally advanced pancreatic cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Locally Advanced Pancreatic Cancer Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/locally-advanced-pancreatic-cancer-global-market-report

Browse Through More Reports Similar to the Global Locally Advanced Pancreatic Cancer Market 2026, By The Business Research Company

Invasive Ductal Carcinoma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/invasive-ductal-carcinoma-therapeutics-global-market-report

Pancreatic Cancer Drugs Market Report

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

Gastroesophageal Junction Adenocarcinoma Therapeutics Market Report

https://www.thebusinessresearchcompany.com/report/gastroesophageal-junction-adenocarcinoma-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Locally Advanced Pancreatic Cancer Market Over The Period 2026–2030?

The market size for locally advanced pancreatic cancer has seen rapid expansion in recent years. Projections indicate it will expand from $1.05 billion in 2025 to $1.16 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.5%. Historically, this growth can be ascribed to factors such as the late-stage diagnosis of pancreatic cancer, restricted surgical eligibility for locally advanced cases, a longstanding dependence on gemcitabine-based chemotherapy, low overall survival rates, and the expansion of hospital-based oncology care.

The market size for locally advanced pancreatic cancer is set to experience swift expansion over the coming years, with projections indicating it will reach $1.71 billion by 2030, achieving a compound annual growth rate (CAGR) of 10.2%. This anticipated growth can be credited to the wider implementation of combination therapy protocols, the increasing uptake of SBRT, a surge in investment dedicated to pancreatic cancer research, a heightened focus on personalized oncology care, and the growing accessibility of advanced treatment centers. Significant trends observed during this forecast period include the escalating use of combination chemotherapy regimens, the rising adoption of neoadjuvant treatment approaches, an increased emphasis on tumor downstaging to enhance surgical eligibility, the broadening application of radiation therapy for managing local disease, and a strengthening focus on multidisciplinary strategies for treatment planning.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21214&type=smp

What Drivers Are Expected To Influence The Locally Advanced Pancreatic Cancer Market During The Forecast Period?

The rising incidence of tobacco consumption is anticipated to propel the growth of the locally advanced pancreatic cancer markets in the foreseeable future. Tobacco, a plant cultivated for its leaves used in products like cigarettes and cigars, contains nicotine, an addictive compound associated with severe health problems including cancer and heart disease. The uptick in tobacco use is influenced by elements such as ready availability, affordability, targeted marketing, societal acceptance in specific areas, and smoking prompted by stress. This consumption represents a significant risk factor for the onset of locally advanced pancreatic cancer, contributing to a higher prevalence of pancreatic malignancies. Illustratively, in October 2024, a study on youth smoking trends by the European Respiratory Society’s (ERS), a Switzerland-based non-profit organization, indicated a notable increase in smoking rates, with 22.5% of respondents smoking in 2022 escalating to 40.1% in 2024. Hence, the observed growth in tobacco consumption is a key driver for the expansion of the locally advanced pancreatic cancer market.

How Is The Locally Advanced Pancreatic Cancer Market Divided Into Its Major Segments?

The locally advanced pancreatic cancer market covered in this report is segmented –

1) By Therapy: Chemotherapy, Radiation Therapy

2) By Route Of Administration: Oral, Injectables, Other Routes Of Administrations

3) By End-User: Hospital, Specialty Clinics, Research Institutions, Other End-Users

Subsegments:

1) By Chemotherapy: Gemcitabine-based Chemotherapy, FOLFIRINOX Chemotherapy

2) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Body Radiation Therapy (SBRT)

Which Trends Are Influencing The Locally Advanced Pancreatic Cancer Market?

Companies operating within the locally advanced pancreatic cancer market are prioritizing the development of innovative products, including orphan drugs, to enhance available treatment options, improve patient outcomes, and address significant unmet medical needs associated with this aggressive disease. Orphan drugs are specifically developed for rare conditions impacting a small number of individuals, receiving encouragement from regulatory authorities through benefits like tax reductions and market exclusivity to stimulate their development. For example, in January 2025, Actuate Therapeutics Inc., a US-based biopharmaceutical company, announced that its compound, Elraglusib, a new GSK-3β inhibitor, was granted Orphan Drug Designation by both the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) for the treatment of pancreatic ductal adenocarcinoma (PDAC) (a potential types of locally advanced pancreatic cancer). This designation underscores its potential to bridge a critical gap in treating this severe cancer, especially given promising Phase 2 trial results that showed substantial clinical improvements and anti-tumor effects in metastatic PDAC patients.

Who Are The Prominent Organizations Shaping The Locally Advanced Pancreatic Cancer Market?

Major companies operating in the locally advanced pancreatic cancer market are Pfizer Inc, F Hoffmann La Roche Ltd, Merck and Co Inc, Bristol Myers Squibb Company, AstraZeneca plc, AbbVie Inc, Novartis AG, GSK plc, Bayer AG, Eli Lilly and Company, Ipsen, Takeda Pharmaceutical Company Limited, Amgen Inc, Sanofi, Servier, NovoCure Limited, Halozyme Therapeutics, Clovis Oncology, Astellas Pharma, BeiGene

Read the full locally advanced pancreatic cancer market report here:

https://www.thebusinessresearchcompany.com/report/locally-advanced-pancreatic-cancer-global-market-report

Which Region Is Forecast To Lead The Locally Advanced Pancreatic Cancer Market In Terms Of Market Size?

North America was the largest region in the locally advanced pancreatic cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Locally Advanced Pancreatic Cancer Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21214&type=smp

Browse Through More Reports Similar to the Global Locally Advanced Pancreatic Cancer Market 2026, By The Business Research Company

Invasive Ductal Carcinoma Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/invasive-ductal-carcinoma-therapeutics-global-market-report

Pancreatic Cancer Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

Gastroesophageal Junction Adenocarcinoma Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/gastroesophageal-junction-adenocarcinoma-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model